






PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International BureauRTMP COPY
+
IPER +
Annexe +
Replacement
sheets

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) sheets

(51) International Patent Classification 6: C07D 453/02, 453/06, 487/08, A61K 31/445, C07F 5/02	A1	(11) International Publication Number: WO 97/30998 (43) International Publication Date: 28 August 1997 (28.08.97)
(21) International Application Number: PCT/SE97/00294 ✓ (22) International Filing Date: 21 February 1997 (21.02.97) ✓ (30) Priority Data: 9600683-8 23 February 1996 (23.02.96) ✓ SE (71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). ✓ (72) Inventors; and (75) Inventors/Applicants (for US only): MACOR, John [US/US]; 95 Bracloch Crossing, Penfield, NY 14526 (US). WU, Edwin [US/US]; 147 Ashley Drive, Rochester, NY 14620 (US). (74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. With amended claims.	

(54) Title: AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY**(57) Abstract**

A compound of formula (I) wherein: A is (II), (III), (IV) or (V); X is O or S; Y is O or S; G and D are independently nitrogen or carbon with the proviso that no more than one of G, D, or E is nitrogen; E is N or C-R₄; R₁ is hydrogen or methyl; R₂ is hydrogen or fluoro; R₃ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃; R₄ is hydrogen, halogen, C₁ to C₃ alkyl, -OR₅, -CN, -CONH₂, -CO₂R₅, -NR₅R₆ or phenyl optionally substituted with one to three of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃; or R₂ and R₃ or R₃ and R₄ may together represent a fused phenyl ring optionally substituted with one or two of the following substituents: halogen, C₁ to C₃ alkyl, -NO₂, -CN, or -OCH₃; R₅ and R₆ are independently hydrogen or C₁ to C₃ alkyl; or an enantiomer thereof, and pharmaceutically acceptable salts thereof, processes for preparing them, compositions containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, as well as intermediates and use of intermediates in synthesis.